Lemonaid Health
→
23andMe
Acquisition · Cash and stock · ME · announced Oct 22, 2021
Announced
Oct 22, 2021
Closed
Nov 1, 2021
Economics
Cash and stock
$400M purchase price (25% cash, 75% 23andMe Class A stock), subject to customary adjustments per SEC EX-99.1 (Oct 22, 2021)
Target
Lemonaid Health
Mental Health · Consumer wellness
HQ San Francisco, CA · Founded 2013
Telehealth platform with women's health focus
- SEC EDGAR EX-99.1 — 23andMe/Lemonaid merger agreement (Oct 22, 2021)
- Globe Newswire — acquisition closing (Nov 1, 2021)
- Crunchbase - crunchbase.com/organization/lemonaid-health
Acquirer
23andMe (ME)
General Wellness
HQ Sunnyvale, CA
Why this buyer
Curated copy from the verified dataset — not an 8-K LLM summary
Combined consumer genetics with telehealth and mail-order pharmacy to expand into personalized virtual care
Evidence ladder
Primary (regulatory / filing)
SEC EDGAR EX-99.1 (23andMe–Lemonaid merger agreement, Oct 22, 2021)
SEC EDGAR filings (ticker locator)Secondary (press / IR)
Globe Newswire closing release (Nov 1, 2021)
Primary (regulatory / filing)
SEC EDGAR 8-K EX-99.1 (merger agreement, Oct 22, 2021) https://www.sec.gov/Archives/edgar/data/1804591/000119312521305409/d231996dex991.htm
Open sourcePrimary (regulatory / filing)
SEC EDGAR 8-K EX-99.1 (closing, Nov 1, 2021) https://www.sec.gov/Archives/edgar/data/1804591/000119312521316240/d247525dex991.htm
Open source
Limitations
- $400M purchase price (25% cash, 75% 23andMe Class A stock), subject to customary adjustments per SEC EX-99.1 (Oct 22, 2021)
Valuation peers · Mental Health
Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer, until you sort.
Insufficient disclosed data
No verified Mental Health deals meet the peer rule: same deal type, announced within ±3 years, and a disclosed value inside 0.25×–4× of this transaction.
Other verified deals by 23andMe
Acquirer program history not already listed as a valuation peer or adjacency row.
No further verified deals
Other verified transactions by 23andMe are already listed above, or none are in the dataset.
Patient empowerment context
Patient empowerment baseline (HLTH 2022)
No curated mapping — Lemonaid Health (Mental Health). HLTH/Outcomes4Me 2022 baseline is Breast cancer care continuum (HLTH 2022). No curated mapping for this target in the verified crosswalk.
Research workspace (includes heuristic crosswalk) →Related verified workspaces
Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.
Curated verified dataset v11 · updated 2026-10-19 · 4 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.